Article PDF
Avoid common mistakes on your manuscript.
References
Bernard C (1877) Lecons sur le Diabète. J-B Bailière, Paris
Li CH (1964) Lipotropin, a new active peptide from pituitary gland. Nature 201: 924
Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. Science 179: 1011–1014
Wong DT, Horng JS (1973) Stereospecific interaction of opiate narcotics in binding of 3H-dihydromorphine to membrane of rat brain. Life Sci 13: 1543–1556
Terenius L, Wahlström A (1975) Search for an endogenous ligand for the opiate receptor. Acta Physiol Scand 94: 74–81
Hughes J (1975) Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 88: 295–308
Akil H, Watson ST, Young E, Lewis M, Khachatarieu J, Walker JM (1984) Endogenous opioids: biology and function. Annu Rev Neurosci 7: 233–255
Krieger DT, Liotta AS, Brownstein MJ, Zimmerman EA (1980) ACTH, β-lipoprotein and related peptides in brain, pituitary and bloos. Acta Endocrinol (Copenh) 104: 85–90
Krieger DT (1983) Brain peptides: what, where and why? Science 222: 975–985
Hughes J, Kosterlitz HW (1983) Opioid peptides: introduction. Br Med Bull 39: 1–13
Rossier J (1982) Opioid peptides have found their roots. Nature 298: 221–222
Noda M, Furutani Y, Takahashi H, Tiyusato M, Hirose T, Inayama S, Nakanishi S, Numa S (1982) Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 295: 202–206
Noda M, Teranishi Y, Takahashi H, Furutani Y, Hirose T, Inayama S, Nakanishi S, Numa S (1982) Isolation and structural organization of the human preproenkephalin gene. Nature 297: 431–434
Kadikani H, Furutani Y, Takahashi H, Noda M, Morimoto Y, Hirose T, Asai M, Inayama S, Nakanishi S, Numa S (1982) Cloning and sequence analysis of cDNA for porcine B-neoendorphin-dynorphin precursor. Nature 298: 245–249
Jacqet YF, Marks N (1976) The c-fragment of beta-lipotropin: an endogenous neuroleptic or antipsychotogen? Science 194: 632–635
Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides-Multiple agonists and receptors. Nature 267: 495–499
Wuster M, Schulz R, Herz A (1981) Multiple opiate receptors in peripheral tissue preparations. Biochem Pharmacol 30: 1883–1887
Chang KJ, Cuatrecasas P (1981) Heterogeneity and properties of opiate receptors. Fed Proc 40: 2729–2734
Feldberg W, Gupta KP (1974) Morphine hyperglycaemia. J Physiol (Lond) 238: 487–502
Borison HL, Fishburn BR, Bhide NK, McCarthy LE (1962) Morphine-induced hyperglycaemia in the cat. J Pharmacol Exp Ther 138: 229–235
Feldberg W, Shaligram SV (1972) The hyperglycaemic effect of morphine. Br J Pharmacol 46: 602–618
Van Loon GR, Appel NM, Ho D (1981) β-endorphin-induced stimulation of central sympathetic outflow: β-endorphin increase plasma concentrations of epinephrine, norepinephrine, and dopamine in rats. Endocrinology 109: 4653
Feldberg W, Pyke DA, Stubbs WA (1985) On the origin of noninsulin-dependent diabetes. Lancet I: 1263–1264
Matsumura M, Fukushima T, Saito H, Saito S (1984) In vivo and in vitro effects of β-endorphin on glucose metabolism in the rat. Horm Metabol Res 16: 27–31
Brubaker PL, Sun A, Vranic M (1987) Lack of effect of β-endorphin on basal and glucagon-stimulated hepatic glucose production in vitro. Metabolism 36: 432–437
Allan EH, Green IC, Titheradge MA (1983) The stimulation of glygogenolysis and neoglucogenesis in isolated hepatocytes by opiate peptides. Biochem J 216: 507–510
Leach RP, Allan EH, Titheradge MA (1985) The stimulation of glycogenolysis in isolated hepatocytes by opioid peptides. Biochem J 227: 191–197
Dave JR, Rubinstein N, Eskay RL (1985) Evidence that β-endorphin binds to specific receptors in rat peripheral tissues and stimulates the adenylate cyclase-adenosine 3′,5′-monophosphate system. Endocrinology 117: 1389–1396
Radosevich PM, Williams PE, McRae JR, Lacy WW, Orth DN, Abumrad NN (1984) β-endorphin inhibits glucose production in the conscious dog. J Clin Invest 73: 1237–1241
Houghten RA, Swann RW, Li CH (1980) β-endorphin: stability, clearance behaviour, and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits. Proc Natl Acad Sci USA 77: 4588–4591
Rapoport SI, Klee WA, Pettigrew KD, et al. (1980) Entry of opioid peptides into the central nervous system. Science 207: 84–86
Pardridge WM (1981) Transport of nutrients and hormones through the blood-brain barrier. Diabetologia 20: 246–254
Radosevich PM, Williams PE, Brooks Lacy D, McRae JR, Steiner KE, Cherrington AD, Lacy WW, Abumrad NN (1984) Effects of morphine on glucose homeostasis in the conscious dog. J Clin Invest 74: 1473–2480
El-Tayeb KMA, Brubaker PL, Vranic M, Lickley HLA (1985) Beta-endorphin modulation of the glucoregulatory effects of repeated epinephrine infusion in normal dogs. Diabetes 34: 1293–1300
Werther GA, Joffe S, Artal R, Sperling MA (1985) Opiate modulation of glucose turnover in dogs. Metabolism 34: 136–140
Reid RL, Sandler JA, Yen SSC (1981) β-endorphin stimulates the secretion and glucagon in humans. J Clin Endocrinol Metab 52: 592–594
Feldman M, Kiser RS, Unger RH, Li CH (1983) Beta-endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings. N Engl J Med 308: 349–353
Paolisso G, Giugliano D, Scheen AJ, Franchimont P, D'Onofrio F, Lefebvre PJ (1987) Primary role of glucagon release in the effect of β-endorphin on glucose homeostasis in normal man. Acta Endocrinol (Copenh) 115: 161–169
Stubbs WA, Jones A, Edwards CRW, Delitala G, Jeffcoate WJ, Ratter GM, Bloom SR, Alberti KGMM (1978) Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet II: 1225–1226
Giugliano D, Quatraro A, Consoli G, Ceriello A, Torella R, D'Onofrio F (1987) Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non-insulin-dependent diabetic subjects. Metabolism 36: 286–289
Konturek SJ, Tasler J, Cieszkoski M, Jaworek J, Coy DH, Schally AV (1978) Inhibition of pancreatic secretion by enkephalin and morphine in dogs. Gastroenterology 74: 851–855
Bruni JF, Watkins WB, Yen SSC (1979) β-endorphin in the human pancreas. J Clin Endocrinol Metab 49: 649–651
Grube D, Voight KH, Weber E (1978) Pancreatic glucagon cells contain endorphin-like immunoreactivity. Histochemistry 59: 75–79
Polak JM, Bloom SR, Sullivan SN, Facer P (1977) Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet I: 972–974
Ipp E, Dobbs R, Unger RH (1978) Morphine and β-endorphin influence the secretion of the endocrine pancreas. Nature (Lond) 276: 190–191
Hermansen K (1983) Enkephalins and the secretion of pancreatic somatostatin and insulin in the dog: studies in vitro. Endocrinology 113: 1149–1154
Rudman D, Berry CJ, Riedeburg CH, Hollins BM, Kutner MK, Dynn MJ, Chawla RK (1983) Effects of opioid peptides and opiate alkaloids on insulin secretion in the rabbit. Endocrinology 112: 1702–1710
Green IC, Perrin D, Pedley KC, Leslie RDG, Pyke DA (1980) Effects of enkephalins and morphine on insulin secretion from isolated rat islets. Diabetologia 19: 158–161
Sachse G, Laube H, Svedberg J, Breidenbach T, Teschemacher H (1981) Opiates influence endocrine pancreatic secretion. Diabetologia 21: 322 (Abstract)
Ryder S, Gollapudi GM, Ryder D (1980) Morphine sulphate inhibits insulin release from isolated superinfused rat pancreas. Horm Metabol Res 12: 412–413
Kanter RA, Ensinck JW, Fujimoto WY (1980) Disparate effects of enkephalin and morphine upon insulin and glucagon secretion by islet cell cultures. Diabetes 29: 84–86
Toyota T, Ishizuka J, Nagaoka J, Goto Y (1985) Effects of metenkephalin and dynorphin (1–17) on the secretion of insulin and glucagon from the isolated perfused pancreas. In: Sakamoto N, Min HK, Baba S (eds) Current topics in clinical and experimental aspects of diabetes mellitus. Elsevier, Amsterdam, pp 86–90
Toyota T, Ishizuka J, Ono T, Sasaki M, Shimosegawa T, Goto Y (1985) Inhibitory effect of rimorphin on insulin secretion and alpha-adrenergic receptor. Diabetes 34 [Suppl 1]: 165 A
Ipp E, Schusdiarra V, Harris V, Unger RH (1980) Morphine-induced hyperglycaemia: role of insulin and glucagon. Endocrinology 107: 461–463
Ipp E, Dhorajiala J, Pugh W, Poossa AR, Rubenstain AH (1982) Effects of an enkephalin analog on pancreatic endocrine function and glucose homeostasis in normal and diabetic dogs. Endocrinology 111: 2110–2116
Hart IC, Cowie AT (1978) Effect of morphine, naloxone and an enkephalin analogue on plasma prolactin, growth hormone, insulin and thyroxine in goats. J Endocrinol 77: 16–17
Schleicher RL, Chawla RK, Coan PA, Martino-Saltzman D, Collins DC (1987) β-endorphin-induced hyperglicaemia in rabbits: effects of a glucose or arginine challenge. Am J Physiol 252: E255-E259
Iversen J (1973) Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J Clin Invest 52: 2102–2116
Giugliano D (1984) Morphine, opioid peptides, and pancreatic islet function. Diabetes Care 7: 92–98
Lala A, Bouloux P, Tamburrano G, Gale E (1987) Opioid peptides and glucose metabolism. J Endocrinol Invest 10: 95–104
Schusdziarra V, Specht J, Schick R, De la Fuente A, Holland A, Pfeiffer EF (1983) Effect of morphine, Leu-enkephalin and β-casomorphine on basal somatostatin release in dogs. Horm Metabol Res 15: 407–410
Schusdziarra V, Schick A, De la Fuente A, Specht J, Klier M, Brantl V, Pfeiffer EV (1983) Effect of β-casomorphins and analogs on insulin release in dogs. Endocrinology 112: 885–889
Taborsky GJ Jr, Halter JB, Porte D Jr (1982) Morphine suppresses plasma catecholamine responses to laparatomy but not to 2-deoxyglucose. Am J Physiol 242: E317-E322
Giugliano D, Cozzolino D, Salvatore T, Ceriello A, Torella R (1987) Dual effect of Beta-endorphin on insulin secretion in man. Horm Metabol Res 19: 502–503
Rossier J, French ED, Rivier C, Ling N, Guillemin R, Bloom FE (1977) Foot-shock induced stress increases β-endorphin levels in blood butnot in brain. Nature 270: 618–620
Dubois M, Pickar D, Cohen MR, Roth YF, MacNamara T, Bynney WE Jr (1981) Surgical stress in humans is accompanied by an increase in plasma β-endorphin immunoreactivity. Life Sci 29: 1249–1254
Halter JB, Beard JC, Porte D Jr (1984) Islet function and stress hyperglycaemia: plasma glucose and epinephrine interaction. Am J Physiol 247: E47-E52
Caldara R, Testori GP, Ferrari C, et al. (1981) Effect of loperamide, a peripheral opiate agonist, on circulating glucose, free fatty acids, insulin, C-peptide and pituitary hormones in healthy man. Eur J Clin Pharmacol 21: 185–188
Jeanrenaud X, Maeder E, Del Pozo E, Felber JP (1983) Effect of an enkephalin analogue (FK 33-824) on glucose tolerance in man. Acta Endocrinol (Copenh) 104: 85–90
Giugliano D, Ceriello A, Di Pinto P, Saccomanno F, Gentile S, Cacciapuoti F (1982) Impaired insulin secretion in human diabetes mellitus. The effect of naloxone-induced opiate receptor blockade. Diabetes 31: 367–370
Morley JE (1981) The endocrinology of the opiates and opioid peptides. Metabolism 30: 195–208
Reid LD (1985) Endogenous opioid peptides and regulation of drinking and feeding. Am J Clin Nutr 42: 1099–1132
Maickel RP, Braude MC, Zabik JE (1977) The effects of various narcotic agonists and antagonists on deprivation-induced fluid consumption. Neuropharmacol 16: 863–866
Recant L, Voyles NR, Luciano M, Pert CB (1980) Naltrexone reduces weight gain, alters “β-endorphin”, and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1: 309–313
Margules DL, Moisset B, Lewis MJ, Shibuya H, Pert CB (1978) β-endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa). Science 202: 988–991
Ferguson-Segall M, Flynn JJ, Walker J, Margules DL (1982) Increased immunoreactive dynorphin and leuenkephalin in posterior pituitary of obese mice (ob/ob) and super-sensitivity to drugs that act at kappa receptor. Life Sci 31: 2233–2236
Gunion MW, Peters RH (1981) Pituitary β-endorphin, naloxone, and feeding in several experimental obesities. Am J Physiol 241: R173-R184
Morley JE, Levine AS (1982) The role of the endogenous opiates as regulators of appetite. Am J Clin Nutr 35: 757–761
Grandison S, Guidotti A (1977) Stimulation of food intake by muscimol and beta endorphin. Neuropharmacology 16: 533–536
Davis JM, Lowy MT, Yim GKW, Lamb DR, Malven PV (1983) Relationship between plasma concentrations of immunoreactive beta-endorphin and food intake in rats. Peptides 4: 79–83
Rossier J, Rogers J, Shibasaki T, Guillemin R, Bloom FE (1979) Opioid peptides and α-melanocyte-stimulating hormone in genetically obese (ob/ob) mice during development. Proc Natl Acad Sci USA 76: 2077–2080
Morley JE (1980) The neuroendocrine control of appetite; the role of the endogenous opiates, colecystokinin, TRH, gammaaminobutyric acid and the diazepam receptors. Life Sci 27: 355–368
Givens SJR, Wiedemann E, Andersen RN, Kitabchi AE (1980) β-endorphin and β-lipotropin plasma levels in hirsute women: correlation with body weight. J Clin Endocrinol Metab 50: 975–977
Facchinetti F, Giovannini C, Barletta C, Petraglia F, Buzzetti R, Burla F, Lazzari R, Genazzani AR, Scavo D (1986) Hyperendorphinemia in obesity and relationship to affective state. Physiol Behav 36: 937–940
Genazzani AR, Facchinetti F, Petraglia F, Pintor C, Corda R (1986) Hyperendorphinemia in obese children and adolescents. J Clin Endocrinol Metab 62: 36–40
Facchinetti F, Livieri C, Petraglia F, Cortona L, Severi F, Genazzani AR (1987) Dexamethasone fails to suppress hyperendorphinemia of obese children. Acta Endocrinol (Copenh) 116: 90–94
Matsumura N, Fukuda N, Saito S, Mori M (1982) Effect of a test meal, duodenal acidification and tetragastrin on the plasma concentration of B-Endorphin like immunoreactivity in man. Regul Pept 4: 173–181
Getto CJ, Fullerton DT, Carlson IH (1984) Plasma immunoreactive B-Endorphin response to glucose ingestion in human obesity. Appetite 5: 329–334
Scavo D, Facchinetti F, Barletta C, Petraglia F, Buzzetti R, Monaco M, Giovannini C, Genazzani AR (1987) Plasma betaendorphin response to oral glucose tolerance test in obese patients. Horm Metab Res 19: 204–207
Atkinson RL (1982) Naloxone decreases food intake in obese humans. J Clin Endocrinol Metab 55: 196–198
Kyriakides M, Silverstone T, Jeffcoate W, Laurance B (1980) Effect of naloxone on hyperphagia in Prader-Willi syndrome. Lancet I: 876–877
Thompson DA, Welle SL, Lilavivat U, Penicaud L, Campbell RG (1982) Opiate receptor blockade in man reduces 2-deoxy-d-glucose-induced food intake but not hunger, thirst and hypothermia. Life Sci 31: 847–852
Sternbach HA, Annitto W, Pottash ALC, Gold MS (1982) Anorexic effects of naltrexone in man. Lancet I: 388–389
Vettor R, Martini C, Manno M, Cestaro S, Federspil G, Sicolo N (1985) Effects of naloxone-induced opiate receptors blockade on insulin secretion in obesity. Horm Metab Res 17: 374–375
Giugliano D, Salvatore T, Cozzolino D, Ceriello A, Torella R, D'Onofrio F (1987) Sensitivity to β-endorphin as a cause of human obesity. Metabolism 36: 974–978
Givens JM, Kurtz BR, Kitabchi AE, Tittle JB, Karas JG, Mirchell JA, Howes JF (1987) Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade in the polycystic ovary syndrome with acanthosis nigricans. J Clin Endocrinol Metab 64: 377–382
Giugliano D, Salvatore T, Cozzolino D, Torella R, D'Onofrio F (1987) Hyperglycaemia and obesity as determinants of glucose, insulin, and glucagon responses to β-endorphin in human diabetes mellitus. J Clin Endocrinol Metab 64: 1122–1128
Jung RT, Campbell RG, James WPT, Callingham BA (1982) Altered hypothalamic and sympathetic responses to hypoglycaemia in familial obesity. Lancet I: 1043–1046
Leslie RDG, Pyke DA, Stubbs WA (1979) Sensitivity to enkephalin as a cause on non-insulin-dependent diabetes. Lancet I: 341–343
Leslie RDG, Barnett AH, Pyke DA (1979) Chlorpropamide alcohol flushing and diabetic retinopathy. Lancet I: 997–999
Wiles PG, Hoskins P, Leslie RDG, Pyke DA (1984) Prevalence of chlorpropamide alcohol flushing (Letter). Br Med J 288: 328
Wiles PG, Pyke DA (1984) The chlorpropamide alcohol flush. Clinical Science 67: 375–381
Greenberg J, Ellyin F, Pullen G, Ehrenpreis S, Singh AP, Cheng J (1985) Methionine-enkephalin and β-endorphin levels in brain, pancreas, and adrenals of db/db mice. Endocrinology 116: 328–331
Timmers K, Voyles NR, Zalenski C, Wilkins S, Recant L (1986) Altered β-endorphin, Met- and Leu-enkephalins, and enkephalin-containing peptides in pancreas and pituitary of genetically obese diabetic (db/db) mice during development of diabetic syndrome. Diabetes 35: 1143–1151
Forman LJ, Marquis DE, Stevens R, Adler R, Vasilenko P (1985) Diabetes induced by streptozotocin results in a decrease in immunoreactive beta-endorphin levels in the pituitary and hypothalamus of female rats. Diabetes 34: 1104–1107
Awoke S, Voyles NR, Bathena SJ, Tanenberg RJ, Recant L (1984) Alterations of plasma opioid activity in human diabetics. Life Sci 34: 1999–2006
Vermes I, Steinmetz E, Schoorl J, Van der Veen EA, Tilders FJH (1985) Increased plasma levels of immunoreactive β-endorphin and corticotropin in non-insulin-dependent diabetes (Letter). Lancet II: 725–726
Burrin JM, Yeo TH, Kohner EM, Jones J (1986) Plasma immunoreactive β-endorphin in non-insulin-dependent diabetes (Letter). Lancet I: 855
Solerte SB, Petraglia F, Facchinetti F, Genazzani AR, Ferrari E (1985) Dissociation between β-lipotropin and ACTH secretion in type-1 and type-2 diabetes mellitus. J Endocrinol Invest 8 [Suppl 3]: 197A
Reid RL, Sandler JA, Yen SSC (1984) Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus. Metabolism 33: 197–199
Giugliano D, Ceriello A, Salvatore T, Paolisso G, D'Onofrio F, Lefebvre PJ (1987) β-endorphin infusion restores acute insulin responses to glucose in type-2 diabetes mellitus. J Clin Endocrinol Metab 64: 944–948
Giugliano D, Ceriello A, Quatraro A, D'Onofrio F (1987) β-endorphin and the secretion of islet hormones in NIDDM. Diabetes [Suppl 1] 36: 123A
Giugliano D, Cozzolino D, Salvatore T, Ceriello A, Giunta R, Torella R, D'Onofrio F (1988) β-endorphin and islet hormone release in type-2 diabetes mellitus. The effect of normoglycaemia, enkephalin, naloxone and somatostatin. Diabete Metab (in press)
Levine AS, Morley JE, Brown DM, Handwerker BS (1982) Extreme sensitivity of diabetic mice to naloxone-induced suppression of food intake. Physiol Behav 28: 987–989
Giugliano D, Di Pinto P, Ceriello A, Saccomanno F, Passariello N, D'Onofrio F (1985) Impaired insulin secretion in human diabetes mellitus. Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose-induced release. Diabete Metab 11: 350–358
Verlohren HJ, Jahr J (1984) Insulin secretion in type-II diabetes. In vivo and in vitro investigations. Exp Clin Endocrinol 83: 216–224
Passariello N, Giugliano D, Ceriello A, Chiariello A, Sgambato S, D'Onofrio F (1986) Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest 9: 953–957
Passariello N, Giugliano D, Quatraro A, Consoli G, Sgambato S, Torella R, D'Onofrio F (1983) Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism 32: 1163–1165
Giugliano D, Ceriello A, Quatraro A, D'Onofrio F (1985) Endogenous opiates, heroin addiction and non-insulin-dependent diabetes. Lancet II: 769–770
Giugliano D (1985) Secrezione insulinica nel diabete non insulino-dipendente. Gior Ital Diabetol 5: 347–357
Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D'Onofrio F (1982) Increased glycosylated haemoglobin A1 in opiate addicts: evidence for hyperglycaemic effect of morphine. Diabetologia 22: 379 (Letter)
Ceriello A, Dello Russo P, Curcio F, Rossano P (1984) Increased glycosylated proteins in opiate addicts. Diabetes Care 7: 104–105
Ceriello A, Dello Russo P, Niola O, Capezzuto C, Schimizzi S (1983) Fibrinogen levels in opiate addicts. Thromb Haemostas 50: 755 (Letter)
Ceriello A, Dello Russo P, Curcio F, Giugliano D (1985) Mean red cell volume, narcotic addiction and glucose tolerance. Arch Intern Med 145: 1530 (Letter)
Ceriello A, Dello Russo P, Curcio F, Petringa D, D'Ippolito S, Varriale M (1983) Morphine, diabetes and lipid metabolism. Arch Intern Med 143: 1070 (Letter)
Ceriello A, Dello Russo P, Curcio F, Tirelli A, Giugliano D (1984) Depressed antithrombin III biological activity in opiate addicts. J Clin Pathol 37: 1040–1042
Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, Pietrantuono C, Rosato GB (1983) Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report. Thromb Haemostas 50: 633–634
Giugliano D, Quatraro A, Consoli G, Stante A, Simeone V, Ceriello A, Paolisso G, Torella R (1987) Sodium salicylate restores the impaired insulin response to glucose and improves glucose tolerance in heroin addicts. Acta Diabetol Lat 24: 205–212
Gerich J, Karam J, Forsham P (1973) Stimulation of glucagon secretion by epinephrine in man. J Clin Endocrinol Metab 37: 479–480
Clutter WE, Bier DM, Shah SD, Cryer PE (1980) Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66: 94–101
Giugliano D, Ceriello A, Quatraro A, Paolisso G, Varano R, D'Onofrio F (1985) Interaction between epinephrine, prostaglandin E and Met-enkephalin in the regulation of insulin release in man. Diabete Metab 11: 295–302
Jeanrenaud B (1985) An hypothesis on the etiology of obesity: disfunction of the central nervous system as a primary cause. Diabetologia 28: 502–513
Giugliano D, Ceriello A, Torella R, D'Onofrio F (1986) Opiacés et diabète non-insulino-dépendant. Journ Annu Diabétol Hôtel Dieu, pp 185–197
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giugliano, D., Torella, R., Lefèbvre, P.J. et al. Opioid peptides and metabolic regulation. Diabetologia 31, 3–15 (1988). https://doi.org/10.1007/BF00279126
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00279126